Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and AVB-S6-500 in Advanced Urothelial Carcinoma
NCT04004442Phase 1Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of batiraxcept in urothelial carcinoma (UC), sponsored by University of Oklahoma. Primary endpoint: Safety and Tolerability up to 2 years. Started Feb 2020; status: active, not recruiting.
02
Drugs
batiraxcept
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04004442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004442.